Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PTT037
MIFTS: 48

Pituitary Tumors

Categories: Cancer diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Pituitary Tumors

About this section

MalaCards integrated aliases for Pituitary Tumors:

Name: Pituitary Tumors 54 55 43
Pituitary Neoplasms 73

Classifications:

MalaCards categories:
Global: Cancer diseases
See all MalaCards categories (disease lists)


External Ids:

UMLS 73 C0032019
Sources

Summaries for Pituitary Tumors

About this section
NINDS : 54 The pituitary is a small, bean-sized gland that is below the hypothalamus, a structure at the base of the brain, by a thread-like stalk that contains both blood vessels and nerves.  It controls a system of hormones in the body that regulate growth, metabolism, the stress response, and functions of the sex organs via the thyroid gland, adrenal gland, ovaries, and testes.  A pituitary tumor is an abnormal growth of cells within the pituitary gland.  Most pituitary tumors are benign, which means they are non-cancerous, grow slowly and do not spread to other parts of the body; however they can make the pituitary gland produce either too many or too few hormones, which can cause problems in the body. Tumors that make hormones are called functioning tumors, and they can cause a wide array of symptoms depending upon the hormone affected.  Tumors that don’t make hormones are called non-functioning tumors.  Their symptoms are directly related to their growth in size and include headaches, vision problems, nausea, and vomiting.  Diseases related to hormone abnormalities include Cushing’s disease, in which fat builds up in the face, back and chest, and the arms and legs become very thin; and acromegaly, a condition in which the hands, feet, and face are larger than normal.  Pituitary hormones that impact the sex hormones, such as estrogen and testosterone, can make a woman produce breast milk even though she is not pregnant or nursing, or cause a man to lose his sex drive or lower his sperm count.  Pituitary tumors often go undiagnosed because their symptoms resemble those of so many other more common diseases.

MalaCards based summary : Pituitary Tumors, also known as pituitary neoplasms, is related to prolactin producing pituitary tumor and tsh producing pituitary tumor. An important gene associated with Pituitary Tumors is GNAS (GNAS Complex Locus), and among its related pathways/superpathways are Aldosterone synthesis and secretion and Pathways in cancer. The drugs Menthol and Hydrocortisone have been mentioned in the context of this disorder. Affiliated tissues include pituitary, brain and thyroid, and related phenotypes are endocrine/exocrine gland and homeostasis/metabolism

MedlinePlus : 43 Your pituitary gland is a pea-sized gland at the base of your brain. The pituitary is the "master control gland" - it makes hormones that affect growth and the functions of other glands in the body. Pituitary tumors are common, but often they don't cause health problems. Most people with pituitary tumors never even know they have them. The most common type of pituitary tumor produces hormones and disrupts the balance of hormones in your body. This can cause endocrine diseases such as Cushing's syndrome and hyperthyroidism. Symptoms of pituitary tumors include Headaches Vision problems Nausea and vomiting Problems caused by the production of too many hormones Pituitary tumors are usually curable. Treatment is often surgery to remove the tumor. Other options include medicines, radiation therapy, and chemotherapy.

Sources

Related Diseases for Pituitary Tumors

About this section

Diseases related to Pituitary Tumors via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 213)
# Related Disease Score Top Affiliating Genes
1 prolactin producing pituitary tumor 34.3 PRL SST
2 tsh producing pituitary tumor 33.8 GH1 PRL SST
3 gigantism 32.0 AIP GH1 PRL
4 acth-secreting pituitary adenoma 31.6 POMC PRL
5 pituitary apoplexy 31.5 AIP POMC PRL
6 empty sella syndrome 31.4 GH1 IGF1 POMC PRL
7 pituitary adenoma 1, multiple types 31.0 AIP GH1 IGF1 PRL SST
8 galactorrhea 30.7 IGF1 PRL
9 non-functioning pituitary adenoma 30.3 GH1 SST
10 hormone producing pituitary cancer 30.1 AIP GNAS IGF1 MEN1 SST SSTR5
11 insulin-like growth factor i 30.0 GH1 IGF1 PRL
12 lymphocytic hypophysitis 30.0 GH1 POMC
13 pituitary carcinoma 29.9 POMC PRL SST
14 hyperthyroidism 29.8 GH1 GNAS PRL SST
15 multiple endocrine neoplasia, type i 29.7 GNAS MEN1 PRL SST
16 adenohypophysitis 29.6 GH1 POMC PRL
17 chiasmal syndrome 29.4 POMC PRL SST
18 nelson syndrome 29.4 POMC PRL SST
19 growth hormone secreting pituitary adenoma 29.4 AIP GNAS PRL SST
20 pituitary hypoplasia 29.2 POU1F1 PRL
21 small cell cancer of the lung 29.0 POMC RB1 SST
22 mccune-albright syndrome 28.8 GH1 GNAS IGF1 PRL SST
23 pheochromocytoma 28.5 MEN1 POMC SST
24 hyperprolactinemia 28.4 GH1 IGF1 POMC PRL SST
25 thyroid carcinoma, familial medullary 28.2 MEN1 POMC SST SSTR5
26 carney complex variant 28.1 AIP GNAS MEN1 POMC
27 craniopharyngioma 28.1 GH1 IGF1 POU1F1 PRL PROP1
28 pituitary gland disease 27.2 GH1 IGF1 MEN1 POMC POU1F1 PRL
29 functioning pituitary adenoma 27.0 AIP GH1 MEN1 POMC PRL SST
30 hypopituitarism 26.8 GH1 IGF1 POMC POU1F1 PRL PROP1
31 hypothyroidism 26.4 GH1 GNAS IGF1 POMC POU1F1 PRL
32 adenoma 26.2 AIP GH1 GNAS IGF1 MEN1 POMC
33 acromegaly 26.1 AIP GH1 GNAS IGF1 MEN1 POMC
34 posterior pituitary gland neoplasm 11.2
35 secondary adrenal insufficiency 11.2
36 acth-independent macronodular adrenal hyperplasia 10.8
37 primary pigmented nodular adrenocortical disease 10.8
38 fibrous dysplasia/mccune-albright syndrome 10.7 GH1 PRL
39 chronic mountain sickness 10.7 SST VEGFA
40 angiodysplasia 10.7 SST VEGFA
41 villous adenoma 10.7 GNAS SST
42 ovarian cyst 10.7 PRL VEGFA
43 adenomyosis 10.7 PRL VEGFA
44 mammographic density 10.6 IGF1 PRL
45 isolated growth hormone deficiency, type ib 10.5 GH1 IGF1
46 pancreatic gastrinoma 10.5 MEN1 SST
47 pancreatic somatostatinoma 10.5 MEN1 SST
48 peripartum cardiomyopathy 10.4 PRL VEGFA
49 bronchus adenoma 10.4 POMC SST
50 carcinoid tumors, intestinal 10.4 MEN1 SST

Graphical network of the top 20 diseases related to Pituitary Tumors:



Diseases related to Pituitary Tumors
Sources

Symptoms & Phenotypes for Pituitary Tumors

About this section

MGI Mouse Phenotypes related to Pituitary Tumors:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.22 AIP GNAS IGF1 MEN1 POMC POU1F1
2 homeostasis/metabolism MP:0005376 10.21 AIP GNAS IGF1 MEN1 POMC POU1F1
3 growth/size/body region MP:0005378 10.2 AIP GNAS IGF1 MEN1 POMC POU1F1
4 cellular MP:0005384 10.1 AIP GNAS IGF1 MEN1 POMC POU1F1
5 immune system MP:0005387 10.06 GNAS IGF1 MEN1 POMC POU1F1 PRL
6 mortality/aging MP:0010768 9.96 AIP GNAS IGF1 MEN1 POMC POU1F1
7 integument MP:0010771 9.91 RB1 VEGFA AIP GNAS IGF1 POMC
8 liver/biliary system MP:0005370 9.87 AIP GNAS MEN1 POMC PRL RB1
9 neoplasm MP:0002006 9.76 RB1 VEGFA AIP GNAS IGF1 MEN1
10 nervous system MP:0003631 9.65 POMC POU1F1 PRL PROP1 RB1 SST
11 reproductive system MP:0005389 9.17 IGF1 MEN1 POU1F1 PRL PROP1 RB1
Sources

Drugs & Therapeutics for Pituitary Tumors

About this section

Drugs for Pituitary Tumors (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 216)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Menthol Approved Phase 4 2216-51-5 16666
2
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-23-7 5754
3
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
4
Morphine Approved, Investigational Phase 4 57-27-2 5288826
5
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
6
Acetaminophen Approved Phase 4 103-90-2 1983
7
Ibuprofen Approved Phase 4 15687-27-1 3672
8
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83150-76-9 383414 6400441
9
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
10 lanreotide Approved Phase 4,Phase 3 108736-35-2
11
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 38916-34-6, 51110-01-1 53481605
12
Zinc Approved, Investigational Phase 4 7440-66-6 23994
13
Sulfamethoxazole Approved Phase 4 723-46-6 5329
14
Metformin Approved Phase 4 657-24-9 14219 4091
15
Cefazolin Approved Phase 4 25953-19-9 656510 33255
16
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
17
Cefdinir Approved Phase 4 91832-40-5 6915944
18
Dexmedetomidine Approved, Vet_approved Phase 4,Not Applicable 113775-47-6 68602 5311068
19
Liraglutide Approved Phase 4 204656-20-2 44147092
20
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
21
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
22
leucovorin Approved, Nutraceutical Phase 4,Phase 1 58-05-9 143 6006
23
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 59-30-3 6037
24
Butyric Acid Experimental, Investigational Phase 4,Not Applicable 107-92-6 264
25
Lactitol Investigational Phase 4,Phase 3 585-86-4 3871
26 glucocorticoids Phase 4,Phase 2,Phase 1,Not Applicable
27 Central Nervous System Depressants Phase 4,Phase 1,Not Applicable
28 Cortisol succinate Phase 4,Phase 3,Phase 2,Not Applicable
29 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Anesthetics Phase 4,Phase 1,Not Applicable
31 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Hydrocortisone 17-butyrate 21-propionate Phase 4,Phase 3,Phase 2,Not Applicable
35 Hydrocortisone acetate Phase 4,Phase 3,Phase 2,Not Applicable
36 Hydrocortisone-17-butyrate Phase 4,Not Applicable
37 Hypnotics and Sedatives Phase 4,Phase 1,Not Applicable
38 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 1,Not Applicable
39 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 insulin Phase 4,Phase 3,Phase 2
41 Analgesics Phase 4,Not Applicable
42
protease inhibitors Phase 4,Phase 1,Not Applicable
43 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Narcotics Phase 4,Not Applicable
45 Cyclooxygenase Inhibitors Phase 4
46 Analgesics, Non-Narcotic Phase 4,Not Applicable
47 HIV Protease Inhibitors Phase 4,Phase 1,Not Applicable
48 Angiopeptin Phase 4,Phase 3
49 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
50 Anti-Bacterial Agents Phase 4,Not Applicable

Interventional clinical trials:

(show top 50) (show all 142)
# Name Status NCT ID Phase Drugs
1 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
2 Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors Completed NCT02351700 Phase 4 IV Caldolor (IV Ibuprofen);IV Ibuprofen placebo
3 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
4 Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients Completed NCT00642720 Phase 4 Pegvisomant
5 Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly Completed NCT00461149 Phase 4 Octreotide-LAR
6 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
7 Preoperative Octreotide Treatment of Acromegaly Completed NCT00521300 Phase 4 Octreotide
8 Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor Removal by Transphenoid Approach Recruiting NCT03132259 Phase 4 high dose dexmedethomidine;low dose dexmedethomidine
9 Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery Recruiting NCT02549768 Phase 4 Dexmedetomidine;Sodium Chloride 0.9%
10 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
11 Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
12 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Recruiting NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
13 A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. Terminated NCT01861717 Phase 4 lanreotide
14 Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Completed NCT00889525 Phase 3 Cabergoline
15 Cabergoline in Nonfunctioning Pituitary Adenomas Completed NCT03271918 Phase 3 Cabergoline
16 Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma Completed NCT00690898 Phase 3 Lanreotide autogel 120 mg
17 An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. Completed NCT01582061 Phase 3 Pasireotide sub-cutaneous
18 Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly Completed NCT01137682 Phase 3 Pasireotide;octreotide LAR 30mg;lanreotide ATG 120mg
19 Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas Completed NCT01620138 Phase 2, Phase 3 Pasireotide;cabergoline
20 Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients Completed NCT00383708 Phase 3 lanreotide (Autogel formulation);Pegvisomant
21 Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease Completed NCT01374906 Phase 3 pasireotide LAR;SOM230 LAR 30 mg;SOM230 LAR 10 mg
22 Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome Completed NCT01371565 Phase 3 Mifepristone
23 Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease Completed NCT00434148 Phase 3 Pasireotide
24 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Recruiting NCT02419664 Phase 3
25 Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas Recruiting NCT02288962 Phase 3 cabergoline
26 Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease Recruiting NCT02697734 Phase 3 osilodrostat;osilodrostat Placebo
27 Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease Active, not recruiting NCT02180217 Phase 3 LCI699
28 Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma Not yet recruiting NCT03439709 Phase 3 Lanreotide 60Mg Solution for Injection
29 Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients Terminated NCT00642421 Phase 3 C2L-OCT-01 PR, 10 or 20 mg;C2L-OCT-01 PR, 20 mg
30 Mifepristone in Children With Refractory Cushing's Disease Withdrawn NCT01925092 Phase 3 mifepristone
31 Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease Unknown status NCT02484755 Phase 2 Gefitinib
32 Preoperative Bexarotene Treatment for Cushing's Disease Unknown status NCT00845351 Phase 1, Phase 2 Bexarotene
33 Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors Completed NCT01689727 Phase 2 Technetium Tc 99m EC20
34 Sandostatin LAR Depot vs. Surgery for Treating Acromegaly Completed NCT00001860 Phase 2 Sandostatin LAR Depot versus transsphenoidal surgery
35 Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities Completed NCT00054756 Phase 2 TRH (Thyrotropin Releasing Hormone)
36 Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma. Completed NCT01283542 Phase 2 Pasireotide LAR
37 Clomiphene in Males With Prolactinomas and Persistent Hypogonadism Completed NCT00697814 Phase 2 Clomiphene citrate
38 Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's Disease Completed NCT00171951 Phase 2 Pasireotide
39 A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease Completed NCT00088608 Phase 2 SOM230 s.c.
40 Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors Recruiting NCT02749227 Phase 2 Pasireotide LAR
41 Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy Recruiting NCT00939523 Phase 2 Lapatinib
42 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
43 Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition Recruiting NCT03111810 Phase 2 AZD4017 and prednisolone;Placebo Oral Tablet and prednisolone
44 Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole Recruiting NCT03038308 Phase 1, Phase 2 Ropinirole
45 Treatment of Cushing's Disease With R-roscovitine Recruiting NCT02160730 Phase 2 R-roscovitine
46 Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease Active, not recruiting NCT01915303 Phase 2 Pasireotide with or without cabergoline
47 Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas Active, not recruiting NCT01966809 Phase 2 Photofrin photodynamic therapy.
48 Safety and Efficacy of LCI699 in Cushing's Disease Patients. Active, not recruiting NCT01331239 Phase 2 LCI699
49 Rosiglitazone in Treating Patients With Pituitary Tumors Terminated NCT00616642 Phase 2 rosiglitazone maleate
50 Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease) Terminated NCT00612066 Phase 2 rosiglitazone maleate

Search NIH Clinical Center for Pituitary Tumors

Inferred drug relations via UMLS 73 / NDF-RT 51 :
Sources

Genetic Tests for Pituitary Tumors

About this section
Sources

Anatomical Context for Pituitary Tumors

About this section

MalaCards organs/tissues related to Pituitary Tumors:

41
Pituitary, Brain, Thyroid, Testes, Hypothalamus, Ovary, Adrenal Gland
Sources

Publications for Pituitary Tumors

About this section

Articles related to Pituitary Tumors:

(show top 50) (show all 881)
# Title Authors Year
1
Baculovirus-based gene silencing of Humanin for the treatment of pituitary tumors. ( 29352443 )
2018
2
The role of galectin-3 in the tumorigenesis and progression of pituitary tumors. ( 29545898 )
2018
3
Advances and controversies in the classification and grading of pituitary tumors. ( 29858984 )
2018
4
Detection of circulating tumor cells in patients with pituitary tumors. ( 29587659 )
2018
5
Genomic Alterations in Sporadic Pituitary Tumors. ( 29396598 )
2018
6
Management of nonfunctioning pituitary tumors: radiotherapy. ( 29372392 )
2018
7
Interleukin-6/signal transducer and activator of transcription 3 promotes prostate cancer resistance to androgen deprivation therapy via regulating pituitary tumor transforming gene 1 expression. ( 29288516 )
2018
8
Welcoming the new WHO classification of pituitary tumors 2017: revolution in TTF-1-positive posterior pituitary tumors. ( 29500747 )
2018
9
Excellence in the treatment of patients with pituitary tumors. ( 29124563 )
2018
10
Transsphenoidal Surgery for Pituitary Tumors and Other Sellar Masses. ( 29056398 )
2018
11
Dysregulation of cell cycle in animal models and human neuroendocrine pituitary tumors (PitNET). ( 29504817 )
2018
12
Leptin Involvement in Primary Brain and Pituitary Tumors: Therapeutic Potential, Prognostic Value, and Proposed Diagnostic Application. ( 29464548 )
2018
13
Headaches in Patients with Pituitary Tumors: a Clinical Conundrum. ( 29974273 )
2018
14
Endoscopic Endo-Nasal Trans-Sphenoidal Excision of Pituitary Tumors: An Institutional Experience. ( 29456951 )
2018
15
Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions. ( 29963012 )
2018
16
Expression of MMP-9, PTTG, HMGA2, and Ki-67 in ACTH-secreting pituitary tumors and their association with tumor recurrence. ( 29432944 )
2018
17
Clinical Presentation and Management of Headache in Pituitary Tumors. ( 29904889 )
2018
18
65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update. ( 29535142 )
2018
19
Expression and clinical significance of EGR-1 and PTEN in the pituitary tumors of elderly patients. ( 28789441 )
2017
20
Neuroretinal evaluation using optical coherence tomography in patients affected by pituitary tumors. ( 28447589 )
2017
21
Overview of the 2017 WHO Classification of Pituitary Tumors. ( 28766057 )
2017
22
First Report of Coexistence of Two Ectopic Pituitary Tumors: Rathke Cleft Cyst and Silent Adrenocorticotropic Hormone Adenoma. ( 28532906 )
2017
23
A Comparison of Dexmedetomidine and Clonidine in Attenuating the Hemodynamic Responses at Various Surgical Stages in Patients Undergoing Elective Transnasal Transsphenoidal Resection of Pituitary Tumors. ( 29284879 )
2017
24
Prognostic factors of regrowth in nonfunctioning pituitary tumors. ( 29288467 )
2017
25
Autocrine IL-6 mediates pituitary tumor senescence. ( 27902467 )
2017
26
Epigenetics of pituitary tumors: Pathogenetic and therapeutic implications. ( 28711607 )
2017
27
Transient Exacerbation of Nasal Symptoms following Endoscopic Transsphenoidal Surgery for Pituitary Tumors: A Prospective Study. ( 28593114 )
2017
28
MicroRNAs in pituitary tumors. ( 28089822 )
2017
29
FGFR4 polymorphic alleles modulate mitochondrial respiration: A novel target for somatostatin analog action in pituitary tumors. ( 27966451 )
2017
30
Authors' Reply: Comprehensive neuro-ophthalmological assessment in pituitary tumors. ( 28488670 )
2017
31
Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas. ( 28432119 )
2017
32
Integrated in silico-in vitro characterization, identification and disruption of the intermolecular interaction between SH3 domain-containing protein kinases and human pituitary tumor-transforming gene 1. ( 27787230 )
2017
33
Clinical profile of silent growth hormone pituitary adenomas; higher recurrence rate compared to silent gonadotroph pituitary tumors, a large single center experience. ( 29043561 )
2017
34
Non-functioning pituitary tumors: any special considerations during pregnancy? ( 29265782 )
2017
35
Dopamine receptor type 2 (DRD2) and somatostatin receptor type 2 (SSTR2) agonists are effective in inhibiting proliferation of progenitor/stem-like cells isolated from nonfunctioning pituitary tumors. ( 28120505 )
2017
36
Fatal antiphospholipid syndrome following endoscopic transnasal-transsphenoidal surgery for a pituitary tumor: A case report. ( 28072724 )
2017
37
Full-field perimetry in pituitary tumors. ( 28488669 )
2017
38
MicroRNA-524-5p Functions as a Tumor Suppressor in a Human Pituitary Tumor-Derived Cell Line. ( 28472828 )
2017
39
Recent Progress in the Medical Therapy of Pituitary Tumors. ( 28685507 )
2017
40
Histone deacetylase 11 suppresses p53 expression in pituitary tumor cells. ( 28782861 )
2017
41
A case of central pontine and extrapontine myelinolysis after surgery for a pituitary tumor. ( 27980288 )
2017
42
Acute hypopituitarism associated with periorbital swelling and cardiac dysfunction in a patient with pituitary tumor apoplexy: a case report. ( 28835258 )
2017
43
The Stem Cell Connection of Pituitary Tumors. ( 29255445 )
2017
44
Clinical Identification of Oncogenic Drivers and Copy-Number Alterations in Pituitary Tumors. ( 28486603 )
2017
45
Assessment of Cost Drivers in Transsphenoidal Approaches for Resection of Pituitary Tumors Using the Value-Driven Outcome Database. ( 28583451 )
2017
46
Pregnancy promotes pituitary tumors by increasing the rate of the cell cycle. ( 29085495 )
2017
47
Berberine Inhibits Uterine Leiomyoma Cell Proliferation via Downregulation of Cyclooxygenase 2 and Pituitary Tumor-Transforming Gene 1. ( 27799459 )
2017
48
Corticotroph pituitary carcinoma in a patient with Lynch syndrome (LS) and pituitary tumors in a nationwide LS cohort. ( 28938458 )
2017
49
The Utility of Magnetic Resonance Imaging in Assessing Patients With Pituitary Tumors Compressing the Anterior Visual Pathway. ( 27391942 )
2016
50
Adenoid Cystic Carcinoma Metastatic to the Pituitary: A Case Report and Discussion of Potential Diagnostic Value of Magnetic Resonance Elastography in Pituitary Tumors. ( 27018011 )
2016
Sources

Variations for Pituitary Tumors

About this section

Cosmic variations for Pituitary Tumors:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM5663 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,functioning c.133T>C p.S45P 3:41224645-41224645 4
Sources

Expression for Pituitary Tumors

About this section
Search GEO for disease gene expression data for Pituitary Tumors.
Sources

Pathways for Pituitary Tumors

About this section

Pathways related to Pituitary Tumors according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Aldosterone synthesis and secretion 37
Show member pathways
 12.58 AIP GNAS MEN1 POMC RB1
2
Pathways in cancer 37
12.52 GNAS IGF1 RB1 VEGFA
3
Glioma 37
Show member pathways
 12.37 GNAS IGF1 RB1 VEGFA
4
PI3K-Akt signaling pathway 37
Show member pathways
 11.93 GH1 GNAS IGF1 PRL RB1 VEGFA
5
Peptide hormone metabolism 66
Show member pathways
 11.89 GH1 IGF1 POMC
6
Adipogenesis 1
11.66 GH1 IGF1 RB1
7
Glucocorticoid receptor regulatory network 1
11.35 POMC POU1F1 PRL
8
Endochondral Ossification 1
11.14 GH1 IGF1 VEGFA
9
Development_Leptin signaling via JAK/STAT and MAPK cascades 22
Show member pathways
 10.95 POMC VEGFA
10
AHR Pathway 64
10.83 AIP RB1
11
Aryl Hydrocarbon Receptor 1
10.81 AIP RB1 VEGFA
Sources

GO Terms for Pituitary Tumors

About this section

Cellular components related to Pituitary Tumors according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.5 GH1 GNAS IGF1 POMC PRL SST
2 endosome lumen GO:0031904 8.62 GH1 PRL

Biological processes related to Pituitary Tumors according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 9.91 MEN1 POU1F1 PROP1 RB1 VEGFA
2 glucose homeostasis GO:0042593 9.65 IGF1 POMC SSTR5
3 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.61 GH1 IGF1 VEGFA
4 regulation of multicellular organism growth GO:0040014 9.58 IGF1 PRL
5 positive regulation of JAK-STAT cascade GO:0046427 9.57 GH1 PRL
6 positive regulation of receptor internalization GO:0002092 9.56 GH1 VEGFA
7 myoblast differentiation GO:0045445 9.55 IGF1 RB1
8 negative regulation of cell proliferation GO:0008285 9.55 MEN1 POU1F1 RB1 SST SSTR5
9 tissue homeostasis GO:0001894 9.54 GNAS RB1
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.54 GH1 IGF1 VEGFA
11 positive regulation of transcription regulatory region DNA binding GO:2000679 9.52 IGF1 RB1
12 response to nutrient levels GO:0031667 9.5 GH1 IGF1 PRL
13 positive regulation of transcription by RNA polymerase II GO:0045944 9.5 IGF1 MEN1 POMC POU1F1 PROP1 RB1
14 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.49 GH1 PRL
15 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.46 GH1 IGF1
16 adenohypophysis development GO:0021984 9.4 POU1F1 PROP1
17 somatotropin secreting cell differentiation GO:0060126 9.26 POU1F1 PROP1
18 regulation of signaling receptor activity GO:0010469 9.1 GH1 IGF1 POMC PRL SST VEGFA

Molecular functions related to Pituitary Tumors according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.43 GH1 IGF1 VEGFA
2 insulin-like growth factor receptor binding GO:0005159 9.16 GNAS IGF1
3 hormone activity GO:0005179 9.02 GH1 IGF1 POMC PRL SST
4 prolactin receptor binding GO:0005148 8.96 GH1 PRL
Sources

Sources for Pituitary Tumors

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....